345 related articles for article (PubMed ID: 31938065)
21. PiggyBac-engineered T cells expressing a glypican-3-specific chimeric antigen receptor show potent activities against hepatocellular carcinoma.
Wang P; Qin W; Liu T; Jiang D; Cui L; Liu X; Fang Y; Tang X; Jin H; Qian Q
Immunobiology; 2020 Jan; 225(1):151850. PubMed ID: 31522780
[TBL] [Abstract][Full Text] [Related]
22. BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity.
Hickman TL; Choi E; Whiteman KR; Muralidharan S; Pai T; Johnson T; Parikh A; Friedman T; Gilbert M; Shen B; Barron L; McGinness KE; Ettenberg SA; Motz GT; Weiss GJ; Jensen-Smith A
PLoS One; 2022; 17(5):e0266980. PubMed ID: 35507536
[TBL] [Abstract][Full Text] [Related]
23. Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma.
Yu M; Luo H; Fan M; Wu X; Shi B; Di S; Liu Y; Pan Z; Jiang H; Li Z
Mol Ther; 2018 Feb; 26(2):366-378. PubMed ID: 29339014
[TBL] [Abstract][Full Text] [Related]
24. Magnetite Nanoparticles and Spheres for Chemo- and Photothermal Therapy of Hepatocellular Carcinoma in vitro.
Jędrzak A; Grześkowiak BF; Golba K; Coy E; Synoradzki K; Jurga S; Jesionowski T; Mrówczyński R
Int J Nanomedicine; 2020; 15():7923-7936. PubMed ID: 33116509
[TBL] [Abstract][Full Text] [Related]
25. Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC.
Kolluri A; Li D; Li N; Duan Z; Roberts LR; Ho M
Hepatol Commun; 2023 Feb; 7(2):e0022. PubMed ID: 36691969
[TBL] [Abstract][Full Text] [Related]
26. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
Gao H; Li K; Tu H; Pan X; Jiang H; Shi B; Kong J; Wang H; Yang S; Gu J; Li Z
Clin Cancer Res; 2014 Dec; 20(24):6418-28. PubMed ID: 25320357
[TBL] [Abstract][Full Text] [Related]
27. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma.
Tang X; Chen L; Li A; Cai S; Zhang Y; Liu X; Jiang Z; Liu X; Liang Y; Ma D
Drug Deliv; 2018 Nov; 25(1):1484-1494. PubMed ID: 29916268
[TBL] [Abstract][Full Text] [Related]
28. Stepwise targeting and responsive lipid-coated nanoparticles for enhanced tumor cell sensitivity and hepatocellular carcinoma therapy.
Li Y; Miao Y; Chen M; Chen X; Li F; Zhang X; Gan Y
Theranostics; 2020; 10(8):3722-3736. PubMed ID: 32206118
[No Abstract] [Full Text] [Related]
29. Anti-EGFR-iRGD recombinant protein modified biomimetic nanoparticles loaded with gambogic acid to enhance targeting and antitumor ability in colorectal cancer treatment.
Zhang Z; Qian H; Huang J; Sha H; Zhang H; Yu L; Liu B; Hua D; Qian X
Int J Nanomedicine; 2018; 13():4961-4975. PubMed ID: 30214200
[TBL] [Abstract][Full Text] [Related]
30. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
[TBL] [Abstract][Full Text] [Related]
31. Platelet-Mimicking Drug Delivery Nanoparticles for Enhanced Chemo-Photothermal Therapy of Breast Cancer.
Pei W; Huang B; Chen S; Wang L; Xu Y; Niu C
Int J Nanomedicine; 2020; 15():10151-10167. PubMed ID: 33363371
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib encapsulated in nanocarrier functionalized with glypican-3 specific peptide for targeted therapy of hepatocellular carcinoma.
Feng S; Zhou J; Li Z; Appelman HD; Zhao L; Zhu J; Wang TD
Colloids Surf B Biointerfaces; 2019 Dec; 184():110498. PubMed ID: 31536939
[TBL] [Abstract][Full Text] [Related]
33. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin.
Pang N; Shi J; Qin L; Chen A; Tang Y; Yang H; Huang Y; Wu Q; Li X; He B; Li T; Liang B; Zhang J; Cao B; Liu M; Feng Y; Ye X; Chen X; Wang L; Tian Y; Li H; Li J; Hu H; He J; Hu Y; Zhi C; Tang Z; Gong Y; Xu F; Xu L; Fan W; Zhao M; Chen D; Lian H; Yang L; Li P; Zhang Z
J Hematol Oncol; 2021 Jul; 14(1):118. PubMed ID: 34325726
[TBL] [Abstract][Full Text] [Related]
34. 32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma.
Liu X; Gao F; Jiang L; Jia M; Ao L; Lu M; Gou L; Ho M; Jia S; Chen F; Gao W
J Transl Med; 2020 Aug; 18(1):295. PubMed ID: 32746924
[TBL] [Abstract][Full Text] [Related]
35. In vivo Targeting of Liver Cancer with Tissue- and Nuclei-Specific Mesoporous Silica Nanoparticle-Based Nanocarriers in mice.
Ding Z; Wang D; Shi W; Yang X; Duan S; Mo F; Hou X; Liu A; Lu X
Int J Nanomedicine; 2020; 15():8383-8400. PubMed ID: 33149582
[TBL] [Abstract][Full Text] [Related]
36. Hepatocellular Carcinoma Targeting and Pharmacodynamics of Paclitaxel Nanoliposomes Modified by Glycyrrhetinic Acid and Ferric Tetroxide.
Zhao L; Liang L; Guo M; Li M; Yu X; Wang Y; Wang Y
Curr Top Med Chem; 2021 Oct; 21(14):1268-1284. PubMed ID: 34620053
[TBL] [Abstract][Full Text] [Related]
37. Homotypic cell membrane-cloaked biomimetic nanocarrier for the accurate photothermal-chemotherapy treatment of recurrent hepatocellular carcinoma.
Sun Y; Zhai W; Liu X; Song X; Gao X; Xu K; Tang B
J Nanobiotechnology; 2020 Apr; 18(1):60. PubMed ID: 32299505
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of growth of hepatocellular carcinoma by co-delivery of anti-PD-1 antibody and sorafenib using biomimetic nano-platelets.
Da X; Cao B; Mo J; Xiang Y; Hu H; Qiu C; Zhang C; Lv B; Zhang H; He C; Yang Y
BMC Cancer; 2024 Feb; 24(1):273. PubMed ID: 38409035
[TBL] [Abstract][Full Text] [Related]
39. Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma.
Xue H; Yu Z; Liu Y; Yuan W; Yang T; You J; He X; Lee RJ; Li L; Xu C
Int J Nanomedicine; 2017; 12():5271-5287. PubMed ID: 28769563
[TBL] [Abstract][Full Text] [Related]
40. Soluble programmed death ligand-1-induced immunosuppressive effects on chimeric antigen receptor-natural killer cells targeting Glypican-3 in hepatocellular carcinoma.
Chen L; Liu S; Adah D; Sun Q; Liang Z; Ho M; Sun B
Immunology; 2023 Jun; 169(2):204-218. PubMed ID: 36640111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]